These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 12622848)

  • 1. Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms.
    Dubocovich ML; Yun K; Al-Ghoul WM; Benloucif S; Masana MI
    FASEB J; 1998 Sep; 12(12):1211-20. PubMed ID: 9737724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luzindole, a melatonin receptor antagonist, suppresses experimental autoimmune encephalomyelitis.
    Constantinescu CS; Hilliard B; Ventura E; Rostami A
    Pathobiology; 1997; 65(4):190-4. PubMed ID: 9396042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luzindole (N-0774): a novel melatonin receptor antagonist.
    Dubocovich ML
    J Pharmacol Exp Ther; 1988 Sep; 246(3):902-10. PubMed ID: 2843633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and Fluorescence Properties of 4-Cyano and 4-Formyl Melatonin as Putative Melatoninergic Ligands.
    Bartolucci S; Retini M; Fanini F; Paderni D; Piersanti G
    ACS Omega; 2023 Jun; 8(24):22190-22194. PubMed ID: 37360469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melatonin Immunoreactivity in Malignant Small Intestinal Neuroendocrine Tumours.
    Söderquist F; Janson ET; Rasmusson AJ; Ali A; Stridsberg M; Cunningham JL
    PLoS One; 2016; 11(10):e0164354. PubMed ID: 27736994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of melatonin metabolism in humans induced by chemical components from herbs and effective prediction of this risk using a computational model.
    Wang C; Huo X; Tian X; Xu M; Dong P; Luan Z; Wang X; Zhang B; Zhang B; Huang S; Deng S; Ma X
    Br J Pharmacol; 2016 Nov; 173(22):3261-3275. PubMed ID: 27588415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Melatonin on the Extracellular-Regulated Kinase Signal Pathway Activation and Human Osteoblastic Cell Line hFOB 1.19 Proliferation.
    Xiong XC; Zhu Y; Ge R; Liu LF; Yuan W
    Int J Mol Sci; 2015 May; 16(5):10337-53. PubMed ID: 25961946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In cerebrovascular circadian rhythms, EETs keep the beat. Focus on "Rhythmic expression of cytochrome P450 epoxygenases CYP4x1 and CYP2c11 in the rat brain and vasculature".
    Pearce WJ
    Am J Physiol Cell Physiol; 2014 Dec; 307(11):C986-8. PubMed ID: 25273881
    [No Abstract]   [Full Text] [Related]  

  • 9. Original Design of Fluorescent Ligands by Fusing BODIPY and Melatonin Neurohormone.
    Thireau J; Marteaux J; Delagrange P; Lefoulon F; Dufourny L; Guillaumet G; Suzenet F
    ACS Med Chem Lett; 2014 Feb; 5(2):158-61. PubMed ID: 24900790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of photoperiod on hormones, behavior, and immune function.
    Walton JC; Weil ZM; Nelson RJ
    Front Neuroendocrinol; 2011 Aug; 32(3):303-19. PubMed ID: 21156187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating melatonin and the risk of breast and endometrial cancer in women.
    Viswanathan AN; Schernhammer ES
    Cancer Lett; 2009 Aug; 281(1):1-7. PubMed ID: 19070424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular evidence that melatonin is enzymatically oxidized in a different manner than tryptophan: investigations with both indoleamine 2,3-dioxygenase and myeloperoxidase.
    Ferry G; Ubeaud C; Lambert PH; Bertin S; Cogé F; Chomarat P; Delagrange P; Serkiz B; Bouchet JP; Truscott RJ; Boutin JA
    Biochem J; 2005 May; 388(Pt 1):205-15. PubMed ID: 15636586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiological and metabolic functions of melatonin.
    Barrenetxe J; Delagrange P; Martínez JA
    J Physiol Biochem; 2004 Mar; 60(1):61-72. PubMed ID: 15352385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic perspectives for melatonin agonists and antagonists.
    Delagrange P; Atkinson J; Boutin JA; Casteilla L; Lesieur D; Misslin R; Pellissier S; Pénicaud L; Renard P
    J Neuroendocrinol; 2003 Apr; 15(4):442-8. PubMed ID: 12622848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nycthemeral variations of cholecystokinin action on intestinal motility in rats: effects of melatonin and S 20928, a melatonin receptor antagonist.
    Merle A; Faucheron JL; Delagrange P; Renard P; Roche M; Pellissier S
    Neuropeptides; 2000 Dec; 34(6):385-91. PubMed ID: 11162294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of melatonin on motility pattern of small intestine in rats and its inhibition by melatonin receptor antagonist S 22153.
    Merle A; Delagrange P; Renard P; Lesieur D; Cuber JC; Roche M; Pellissier S
    J Pineal Res; 2000 Sep; 29(2):116-24. PubMed ID: 10981825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melatonin, its receptors, and relationships with biological rhythm disorders.
    Delagrange P; Guardiola-Lemaitre B
    Clin Neuropharmacol; 1997 Dec; 20(6):482-510. PubMed ID: 9403224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human pineal physiology and functional significance of melatonin.
    Macchi MM; Bruce JN
    Front Neuroendocrinol; 2004; 25(3-4):177-95. PubMed ID: 15589268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melatonin: an endogenous negative modulator of 12-lipoxygenation in the rat pineal gland.
    Zhang H; Akbar M; Kim HY
    Biochem J; 1999 Dec; 344 Pt 2(Pt 2):487-93. PubMed ID: 10567232
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.